Richard Delacruz

Richard delaCruz is a highly experienced researcher with a background in medicinal and pharmaceutical chemistry, holding a PhD from the University of Utah. Currently serving as a Senior Research Scientist IV at Culmination Bio, Richard has achieved significant advancements in assessing gene variant pathogenicity and collaborating on projects with Intermountain Health. Previously, Richard led the IPG Proteomics Division at Intermountain Healthcare, specializing in Imaging Mass Cytometry and biomarker identification. At the Oklahoma Medical Research Foundation, Richard mentored numerous scientists and made substantial contributions to peer-reviewed publications, including identification and patenting of anti-cancer compounds. Early career positions at the University of Utah involved extensive research and technical work in cell biology and protein dynamics. Richard's academic achievements are complemented by several presentations at international conferences and a strong publication record.